Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), acquiring rights to the latter’s reversible dipeptidyl peptidase 1 (DPP1) inhibitor, HSK31858, for respiratory diseases. Chiesi will assume development, manufacturing, and commercial rights to the molecule in markets outside Greater China, excluding China mainland, Hong Kong, Macau, and Taiwan. An upfront fee of USD 13 million will be paid to Haisco, with Chiesi committing to milestone payments totaling up to USD 462 million. Royalties on future sales will also be paid by Chiesi, though specific details remain undisclosed.
HSK31858: A Potential Anti-Inflammatory for Respiratory Diseases
HSK31858 is an oral, potent, and highly selective small-molecule DPP1 inhibitor currently in the Phase II stage of development in China as an anti-inflammatory agent for bronchiectasis. Bronchiectasis is a long-term condition characterized by the widening of the airways in the lungs, leading to a build-up of excess mucus and increased vulnerability to infection. Respiratory disease is one of Chiesi’s core therapeutic areas, and this deal is seen as a strategic expansion of its presence in the field.- Flcube.com
